chrisvoncsefalvay/vaers-outcomes huggingface dataset:
While at work one day I had started experiencing a real bad headache. I am a teacher. The nurse had took my blood pressure and it was 159/129. I had a substitute take over my class so I went home. When I made it home I wasn't feeling good. I laid down and took a nap. When I had got back up I thought I may have Covid so I drove to get tested for it. I was negative. I came back home and still felt bad. I felt like I needed to throw up. Went I bent down to try to throw up my head went boom and nothing came up. I went to go lay down again. I was laying in the bed and I didn't say anything to my husband when he asked me something. I was just looking at him. He left the room to go downstairs to eat and then came back in and laid next to me in the bed. He said it sounded like I was trying to vomit, but I didn't. I was having a seizure, and I started foaming at the mouth. My husband called 911. When the paramedics came they tried to get me out of the seizure state but couldn't. They took me to the hospital. The doctor said he was going to do a spinal tap and then admitted me to the hospital. The doctor said I had bacterial meningitis. I was unresponsive for 2 days. They had to strap me down because I was fighting everyone because I was not myself at that time. The doctor thought I wasn't going to make it because the bacteria had spread to my brain and through my bloodstream. I came home with a PICC line in my arm so my husband could give me the antibiotics that was prescribed to me intravenously. I was on a couple of different antibiotics and blood clot medicine too. After that I had headaches, eye pain, and neck pain. I was going to try to work from home but my doctor suggested that I take a leave of absence. I was also put on seizure medicine, but I am no longer taking that medicine anymore. Now the doctors are trying to see what's going on with my brain now. I also have a mass on the right side of my nasal sinus cavity. I have an appointment to see a sinus doctor on April 8, 2022. He is going to be deciding if I will need surgery for this or not. I have a problem with short term memory loss now. I haven't had anymore seizures.
Severe anxiety; Stomach hurts; Stool is black; Stomach bleeding; Caller states he has been awake for seven days and has not slept at all since; Weak; Tired; His concentration is shot; Scared; This is a spontaneous report from a contactable consumer (patient). A male patient of an unspecified age received bnt162b2 (PFIZER-BIONTEC COVID-19 mRNA VACCINE, Solution for injection, lot number: not reported), via an unspecified route of administration on 01Oct2021 as dose 2, single for COVID-19 immunization. Medical history and concomitant medications were not reported. Patient previously received bnt162b2 (PFIZER-BIONTEC COVID-19 mRNA VACCINE, Solution for injection, lot number: not reported), via an unspecified route of administration on an unspecified date as dose 1, single for COVID-19 immunization. On an unspecified date in Oct2021, the patient experienced stomach bleeding (medically significant) (patient thought he was having stomach bleeding), he had been awake for seven days and has not slept at all since. No sleep for 5 days now. He was really weak, tired, his concentration was shot and got scared, his stomach got hurt and stool was black. On 05Oct2021, he had severe anxiety. The patient went to see his doctor after the first couple of days, and the doctor checked his vitals but did not say anything else about his inability to sleep. Outcome of the event he had been awake for seven days and has not slept at all since was not recovered while for the other events was unknown.  The lot number for [BNT162B2], was not provided and will be requested during follow up.
Headache, Arthralgia, Palpitations, fluttering in chest, shakey, exhausted Narrative:
Information has been received from a nurse practitioner concerning a female patient, who on an unspecified date, received the series of GARDASIL (lot # unknown). The patient received the vaccine series prior to "her sexual debut". Shortly after engaging in sexual activity, on an unspecified date, the patient developed vaccine type HPV. It was unknown if the patient sought medical attention. At the time of the report the patient's outcome was unknown. Additional information has been requested.
This spontaneous report as received from a 78 years old female patient reporting on himself, with diabetes, cholesterol, hypertension and neuropathy on feet and no drug reactions or allergies, who on approximately on 1996 (on his 62 years old), was vaccinated with dose 1 ZOSTAVAX (lot 3, dose and route not provided). No other co-suspects were reported. Concomitant medications included metformin, NEURONTIN, simvastatin (manufacturer unknown) and lisinopril. At age 62 the patient was in Merck Sharp & Dohme clinical trial for ZOSTAVAX and the patient did state she was given a placebo and after the study was given the real ZOSTAVAX. This year 2012 the patient stated she had an outbreak of shingles and wanted to know if we recommend a booster. The patient sought medical attention and was treated with acyclovir. The outcome of shingles was unknown. The relatedness for shingles was unknown for ZOSTAVAX. Additional information has been requested.
The day after my daughter had her shots she woke up that early morning after around 2:30am with over 103 fever. She then broke out in bumps that looked like bug bites all over her eyes and her eyes swelled up to the point that she couldn't see out of them. I gave her Benadryl and Tylenol and after a day her fever lowered and after a day and a half the swelling in her eyes went away.
Daughter called and reported onset of red eyes, itchy red palms.  By 1:00 PM she had vomiting and swelling of face, particularly around eyes.  Advised to go to ER.  Throat swelling developed on way to ER but breathing unaffected. Patient was given unknown injection in ER and also dosed with diphenydramine and prednisone.  She was not admitted to the hospital and recovered fully by next day.
Pregnant; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (Pregnant) in a 25-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002A21A) for COVID-19 vaccination.     The patient's past medical history included Alcohol addiction (minimal) on 14-Aug-2020. Concurrent medical conditions included Seasonal allergy (Seasonal Allergies). Concomitant products included MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) from August 2020 to an unknown date and IRON from February 2021 to an unknown date for Pregnancy.    On 09-Mar-2021 at 4:15 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 14-Jul-2020 and the estimated date of delivery was 19-Apr-2021. On 09-Mar-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Pregnant). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  thirty-fourth week of the pregnancy.  On 09-Mar-2021, MATERNAL EXPOSURE DURING PREGNANCY (Pregnant) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 14-Aug-2020, Pregnancy test: positive (Positive) Positive. In December 2020, Ultrasound scan: normal (normal) Normal. In January 2021, Ultrasound scan: normal (normal) minor concerns another test done in January 2021, ended up being normal.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant products also included topical hydrocortisone which varies 1 percent and 1 to 3 times  daily route ear used for rash.  Lab tests included, glucose on ??-Jan-2021 had no findings- routine blood panel found patient low on iron.  Conception date of patient was found to be 01 Aug 2020. Number of fetus was found to be one.  Patient was scheduled for second dose on 19-Apr-2021.
Breathing problems that got progressively worse; Emphysema; diagnosed as having emphysema/ It was as bad; Like having elephants sitting on your chest or needing a ventolator to help breath; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (Breathing problems that got progressively worse), EMPHYSEMA (Emphysema), FEELING ABNORMAL (diagnosed as having emphysema/ It was as bad) and CHEST DISCOMFORT (Like having elephants sitting on your chest or needing a ventolator to help breath) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   In February 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In March 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced DYSPNOEA (Breathing problems that got progressively worse), EMPHYSEMA (Emphysema), FEELING ABNORMAL (diagnosed as having emphysema/ It was as bad) and CHEST DISCOMFORT (Like having elephants sitting on your chest or needing a ventolator to help breath). At the time of the report, DYSPNOEA (Breathing problems that got progressively worse), EMPHYSEMA (Emphysema), FEELING ABNORMAL (diagnosed as having emphysema/ It was as bad) and CHEST DISCOMFORT (Like having elephants sitting on your chest or needing a ventolator to help breath) outcome was unknown.            Concomitant product information was not provided. Treatment information was provided but not specified.
t103-104, nausea, vomiting during noc of vax, diarrhea 1 loose BM; seen by MD given APAP supp & Pherengan supp for fever & nausea;
Patient stated that she experienced itchiness and pain at injection site. Slight edema noted at injection site. Pt monitored for 30 minutes afterward. No further progression of swelling or redness noted upon observation period.Pt denied shortness of breath or chest pain. No urticaria noted after assessment completed. VS obtained with assessment.  Pt denied ambulance and AAOX4 with GCS 15 and ambulatory prior to leaving clinic. Form and VAERS completed.
reddsh circular raised area on arm where vaccination recieved; It is painful where I received the vaccine; redness and localized pain; localized pain; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (redness and localized pain), PAIN (localized pain), VACCINATION SITE ERYTHEMA (reddsh circular raised area on arm where vaccination recieved) and VACCINATION SITE PAIN (It is painful where I received the vaccine) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Jan-2021, the patient experienced VACCINATION SITE ERYTHEMA (reddsh circular raised area on arm where vaccination recieved) and VACCINATION SITE PAIN (It is painful where I received the vaccine). In January 2021, the patient experienced ERYTHEMA (redness and localized pain) and PAIN (localized pain). In January 2021, ERYTHEMA (redness and localized pain) and PAIN (localized pain) had resolved. At the time of the report, VACCINATION SITE ERYTHEMA (reddsh circular raised area on arm where vaccination recieved) and VACCINATION SITE PAIN (It is painful where I received the vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not provided. Treatment information was not reported.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Left upper arm red, swollen and warm to touch. 3x3 cm area of swelling. Probable cellulitis. Treated with Keflex 250/5 1.5 tsp po BID x 10 days.
Started sore throat and very hoarse within about 20 minutes after injection.  By the following morning I had shortness of breath upon walking to bathroom, soreness at injection site, paleness, weakness, and a feeling of light headedness. Since the symptoms were fairly severe I called my provider clinic and they advised that I was probably having some type of reaction to the vaccine and to rest take ibuprofen drink fluids and to go to the ER if my breathing worsened or my throat felt like it was going to close up. My symptoms lasted from Thursday PM 11/06/2014 until Sunday AM 11/09/2014.
A spontaneous report had been received from a Physician via Medical representative concerning a 6 years old male patient. No information regarding the relevant history, concomitant disease and concomitant drug was provided. Patient received one dose of FLUMIST QUADRIVALENT (intranasal), 0.2 millilitres, once/single administration on 27-Feb-2016. A day later, the patient developed a seizure, 28-Feb-2016. The BSS (Biotech Sales Specialist) believed that the patient was hospitalized but not sure, patient was in home and was doing ok. Action taken with FLUMIST and the outcome of the event of seizure was unknown. Company physician considered the event of seizure to be serious with seriousness criteria of hospitalization. The patient's neurologist believed seizure was related to the FLUMIST.
20 years old patient vaccinated with Moderna dose 1 (0.5 mL). Vaccinator asked the patient if she received any other vaccine after administering the vaccine. Patient stated she already received 2 doses Dose 1-March 19; Dose 2 - May 1.  Patient stated her PCP advised her to get another vaccine.   PM was notified, escalated to hotline, made aware. Instructed patient that she would not be able to get the Moderna second dose considering she already got WHO approved vaccine and Moderna dose 1.  Educated and reinforced the vaccinator about the importance of asking if patient received any other international vaccine prior to administering  and for any doubts/question she can escalate to leadership.
Developed mild case of chickenpox on 4/17. Approximately 40 lesions, swollen glands, no fever.
Left arm soreness; This is a spontaneous report from a contactable nurse (reporting for herself). A 51-year-old female patient received her second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL8982), via an unspecified route of administration from 28Jan2021 14:45 to 28Jan2021 14:45 at SINGLE DOSE for covid-19 immunization. The patient's medical history included Environmental allergies: some trees and grass. Concomitant medication included bupropion hydrochloride (WELLBUTRIN), loratadine, pseudoephedrine sulfate (CLARITIN-D), montelukast sodium (SINGULAIR), diphenhydramine hydrochloride (BENADRYL), colecalciferol (VITAMIN D [COLECALCIFEROL]), all for unspecified indication. The previously took her first dose of bnt162b2 on 07Jan2021 (lot number: EL3248) on her left arm for covid-19 immunization. On 28Jan2021 at 17:30, the patient experienced Left arm soreness beginning a few hours after vaccine administration and lasting about another 24 hours. The outcome of the event was recovered on an unspecified date. The seriousness of the event was reported as non-serious. The patient was not diagnosed with COVID-19 prior to vaccination. The patient has not been tested for COVID-19 since the vaccination.
couldn't grip anything; hand weakness; hand pain; loss of function of her hand; This case was reported by a consumer via call center representative and described the occurrence of grip strength decreased in a 75-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 26th August 2021, the patient received the 1st dose of Shingrix. On 28th August 2021, 2 days after receiving Shingrix, the patient experienced grip strength decreased, hands weakness of, pain in hand and upper extremity dysfunction. On an unknown date, the outcome of the grip strength decreased, hands weakness of, pain in hand and upper extremity dysfunction were recovered/resolved.   It was unknown if the reporter considered the grip strength decreased, hands weakness of, pain in hand and upper extremity dysfunction to be related to Shingrix.  Additional details were reported as follows; This case was reported by the patient for herself. The patient received Shingrix vaccine and 2 days later developed left hand weakness, left hand pain,  the patient couldn't grip anything in her left hand and reported loss of function of her hand.  The reporter consented to follow-up. This case is linked with US2021AMR213144, reported by the same reporter for the 2nd episode.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR213144:same reporter
no adverse effect; patient received improperly stored pneumovax23; This spontaneous report was received from a pharmacy technician refers to a patient of unknown age. Information on pertinent medical history, concomitant medications and drug reactions or allergies were not reported. On 14-AUG-2019, the patient was vaccinated with improperly stored dose of pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23) (lot # R010724, expiry date: 13-JUN-2020, anatomical location and dose were not reported) via intramuscular route for prophylaxis (product storage error). The vaccine was exposed to a temperature of temperature above 470F/90C (70 F) for a time frame of 4 days which was recorded in a digital data logger. There was no previous temperature excursion noted. No adverse effects reported. No PQC involved.  This is one of the linked reports from same reporter.; Sender's Comments:  US-009507513-1908USA007080:
Pain at injection site immediately lasting 2 days; This is a spontaneous report from a non-contactable consumer, the patient. A 23-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the left arm on 27Aug2021 at 11:00 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medication included unspecified women's vitamin supplement for unknown indication on an unknown date and unknown if ongoing. On 27Aug2021 at 11:15, the patient experienced pain at injection site immediately lasting 2 days. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event pain at injection site immediately lasting 2 days was resolved on 29Aug2021 at 11:15.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Hight Blood Sugar; This spontaneous case was reported by a consumer and describes the occurrence of BLOOD GLUCOSE INCREASED (Hight Blood Sugar) in an 81-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038A21A) for COVID-19 vaccination.     Concurrent medical conditions included Arm discomfort. Concomitant products included LEVOTHYROXINE SODIUM (SYNTHROID), OMEPRAZOLE, TELMISARTAN, METFORMIN, METOPROLOL TARTRATE and TRAMADOL for an unknown indication.    On 26-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Mar-2021, the patient experienced BLOOD GLUCOSE INCREASED (Hight Blood Sugar). At the time of the report, BLOOD GLUCOSE INCREASED (Hight Blood Sugar) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 29-Mar-2021, Blood glucose: 206 (High) Blood sugar was 206. On an unknown date, Blood glucose: 95 (normal) 95 Normal, 98 (normal) 98 Normal, 105 (normal) 105 Normal and unknown (High) Blood sugar was high.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment information was not provided.
Patient came to get vaccinated with elderly parents who were eligible for their second booster dose. Patient's vaccine card stated 3rd dose was on 12/22/22. Vaccine card specifically stated 3rd dose, not booster dose, however patient did not attest to being immunocompromised. No form captured from 4/8/22 or previous dose had an immunocompromised form, hence this was considered her second booster. According to CDC guidelines, second booster is 4 months after first booster, so the patient received their dose 2 weeks too early. No reaction was reported during observation period. Dose #1 4/2. Dose #2 4/26. Dose #3 12/22.
one year old received Flublok with no adverse event; Initial information received on 22-Jul-2022 regarding an unsolicited valid  non-serious case received from a physician.  This case involves a 1 years old male patient who experienced one year old received flublok with no adverse event while receiving vaccine INFLUENZA QUADRIVALENT RECOMBINANT VACCINE [FLUBLOK QIV].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.    On 06-Apr-2022, the patient received a  0.5 ml dose of suspect INFLUENZA QUADRIVALENT RECOMBINANT VACCINE  once  (strength, formulation (lot QFAA2155; expiry date: 30-Jun-2022) via intramuscular route in the right thigh for immunization.  On 06-APR-2022 the patient reported one year old received flublok with no adverse event (off label use) following the administration of INFLUENZA QUADRIVALENT RECOMBINANT VACCINE.  Action taken: not applicable.   At time of reporting, the outcome was Unknown for the event off label use.; Sender's Comments:  01196930:
Case previously recorded as MA2009-4033. Initial case report received from a physician via agency, on 05 NOV 2009. A 33 year-old female patient was vaccinated during pregnancy with 0.5 mL of S-OIV FLUVIRIN (batch no. 100738) i.m on 03 NOV 2009. No adverse events were reported. Agency reference no.: NA09-007596.
got sick.; This case was reported by a consumer via interactive digital media and described the occurrence of sickness in a patient who received Flu Seasonal QIV Dresden (Influenza vaccine Quadrivalent unspecified season) for prophylaxis.   Previously administered products included Flu vaccine with an associated reaction of no adverse event (received for years).   On 2nd November 2020, the patient received Influenza vaccine Quadrivalent unspecified season. On an unknown date, 1 week after receiving Influenza vaccine Quadrivalent unspecified season, the patient experienced sickness. On an unknown date, the outcome of the sickness was unknown.   It was unknown if the reporter considered the sickness to be related to Influenza vaccine Quadrivalent unspecified season.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Flu vaccine and had got sick.
Patient reported arm pain and "arm twitching", which started the day of vaccine and lasted about three days. She said the pain was constant, and the twitching was off and on.